Tissue factor in cancer progression and angiogenesis

Area of Science:

• Oncology
• Hematology
• Cell Biology

Background:

• Constitutive tissue factor (TF) expression in cancer drives thrombosis and tumor progression.
• TF and protease-activated receptor (PAR) 2 are upregulated in breast cancer, correlating with relapse.
• TF signaling via PAR2 and integrins influences angiogenesis and tumor development.

Purpose of the Study:

• To investigate the role of TF signaling in breast cancer progression and angiogenesis.
• To evaluate the therapeutic potential of inhibiting TF-VIIa-PAR2 signaling.

Main Methods:

• Analysis of TF and PAR2 expression in primary breast cancer biopsies.
• Studies in mouse models of spontaneous and xenograft breast cancer.
• Inhibition of TF-VIIa-PAR2 signaling using selective antibodies.

Main Results:

• TF signaling, particularly via PAR2 and integrins, promotes angiogenesis and tumor growth.
• PAR2 deficiency delays breast cancer development and the angiogenic switch in mice.
• Selective antibody inhibition of TF-VIIa-PAR2 signaling suppressed xenograft tumor growth and angiogenesis.

Conclusions:

• TF signaling, independent of its pro-coagulant function, is a key driver of tumor angiogenesis.
• Targeting TF-VIIa-PAR2 signaling offers a promising anti-angiogenic strategy.
• This approach avoids the bleeding risks associated with inhibiting TF's coagulation pathway.